Non-missing sex: (start of available data, 1 day prior to index)
No receipt of elasomeran/davesomeran and andusomeran vaccine: (180 days prior to index, 1 day prior to index)
No evidence of medically attended COVID-19: (180 days prior to index, 1 day prior to index)
No receipt of any other COVID-19 vaccine: (180 days prior to index, index date)
Continuous enrollment in closed medical and pharmacy claims (365 days prior to index, index date)
You may not be if
Vaccine and disease episodes with a prior AESI within the washout window will be excluded from the analytic cohort.
For the influenza vaccinated concurrent comparator cohort, individuals who receive an elasomeran/davesomeran and andusomeran vaccine and an influenza vaccine on the same day or within a minimum number of days will be excluded from the primary analysis.
Clareo Health | Post-marketing Safety of Elasomeran/Davesomeran and Andusomeran
